Allt inom Corporate Information

Invitation to presentation of Nanexa’s Q3 report 2024

Nanexa AB (publ) will publish its report for the third quarter of 2024 on November 7, 2024 and invites to a comment of the report.

All patients have now completed their last visit in Nanexa’s Phase I trial of NEX-22 in Type 2 diabetes

Nanexa AB today announced that all patients have now completed the company’s Phase I study for NEX-22 in type 2 diabetes. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system.